Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that is characterized by uncontrolled myeloid cell divisions in the bone marrow. The disease is caused by a reciprocal translocation between chromosomes and is associated with the Philadelphia chromosome.
Specialists of the Research Laboratory of Immuno-Oncology were the first in the world to create a prognostic score for predicting failure to achieve a complete cytogenetic response in patients with chronic myeloid leukemia in the chronic phase.
The study was conducted in 73 patients who did not have a complete response to treatment before starting the third-line therapy. The score includes data on the age of the patient at the time of the start of the third-line therapy, indicators of cytogenetic response to the first- , second- and before the third-line therapy.
For more, please read the news of the WCRC for Personalized Medicine.